SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 58,800 shares, a decline of 26.3% from the October 15th total of 79,800 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average daily trading volume, of 64,100 shares, the days-to-cover ratio is currently 0.9 days.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SABS. Oppenheimer reissued an “outperform” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a report on Monday, August 12th. Craig Hallum began coverage on shares of SAB Biotherapeutics in a research report on Wednesday, October 9th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday, November 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $12.40.

Institutional Trading of SAB Biotherapeutics

An institutional investor recently bought a new position in SAB Biotherapeutics stock. First PREMIER Bank bought a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned 0.21% of SAB Biotherapeutics at the end of the most recent quarter. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Stock Up 12.6 %

SABS stock traded up $0.41 during trading on Thursday, hitting $3.67. The stock had a trading volume of 146,659 shares, compared to its average volume of 30,333. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average price is $2.93 and its two-hundred day moving average price is $2.98. SAB Biotherapeutics has a 1-year low of $2.16 and a 1-year high of $9.72.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%. Sell-side analysts forecast that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.